FDA Clearance Tracker · P160055-S045
LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)
Last checked: Nov 20, 2026Latest source record: Sep 2, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Sep 2, 2025
Approved
Time to decision
179 days
Received Mar 7, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160055-S045
- Device name
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)
- Applicant
- Rxsight, Inc.
- Applicant location
- Aliso Viejo, CA
- Received
- Mar 7, 2025
- Decided
- Sep 2, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P160055
Device type
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
approval for the professional and patient labeling to include the outcomes of the Post-approval study (PAS) LAL/LDD Postmarket RCT
Source documents
Other decisions for Rxsight, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261174 · Decided Jun 10, 2026 · 62 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
K231838 · Decided Aug 15, 2023 · 54 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
- RxSight Insertion Device510(k)
K231466 · Decided Jun 12, 2023 · 24 days after receipt
Device type: Folders And Injectors, Intraocular Lens (Iol) (MSS) · Ophthalmology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.